Choose Your Horizon, Inc., operating as Choose Ketamine, has extended its health and wellness platform, offering alternative treatments for mental health disorders to an increasing portion of the American population covering more than half of the U.S.
Expanding into new territories, Choose Ketamine now offers services to 110 million citizens across 12 states, providing additional treatment options to those grappling with mental health issues. The company says it will soon provide services to nearly 175 million Americans across 20 states, bringing transformative, evidence-based, patient-first medical care to those suffering from mental health disorders.
Choose Ketamine is aiming to lead the way in transforming the perception of psychedelic medications, many of which have shown the potential to be effective in treating various mental health disorders. With nearly one in five U.S. adults struggling with mental health problems, the potential benefits of KAT could be far-reaching.
Choose Ketamine’s impact has been amplified recently with the inclusion of four states: Arizona, Connecticut, Georgia, and Michigan. The company’s expansion into these regions provides another 31.7 million Americans with the opportunity to consult a healthcare professional about KAT for resistant depression, anxiety, post-traumatic stress disorder (PTSD), and other mental health disorders.
Arizona has solidified Choose Ketamine’s presence across the southwest. With services in Georgia, the company has grown its footprint to cover 34 percent of the southeastern U.S. This expansion puts Choose Ketamine on track to fulfill its mission of making affordable, easy-to-access, and responsible at-home KAT accessible to everyone across the country. Now, the company reaches over half the population in the U.S.
Choose Ketamine’s reach continues to grow, with plans to extend into Oregon, Pennsylvania, New York, and Tennessee in the near future. These expansions will extend KAT services to an additional 32.5 million Americans.
Telemedicine flexibilities, established by the Drug Enforcement Administration (DEA) during the COVID-19 health emergency, have been instrumental in facilitating at-home treatment options. These flexibilities have been extended until November 11, 2023, with practitioner-patient relationships established before that date gaining a full year of additional telemedicine benefits. This extension guarantees that patients will continue to have access to their medication until November 11, 2024.
“The extension of the PHE telemedicine flexibilities is a move in the right direction. This vital decision recognizes that delivering safe and accessible mental healthcare to those in need is critical. By embracing telemedicine, we can reach more individuals, and provide transformative therapies within the comfort of their own homes,” Rob Lee, Choose Ketamine’s COO said in a statement.
Ketamine Therapy
Ketamine is an anesthetic drug that’s been approved for use in the U.S. since the 1970s. In recent years, it has also been recognized for its potential benefits in treating severe depression and other mental health disorders. This is termed as ketamine-assisted therapy (KAT).
Ketamine is currently the only legally approved psychedelic available nationally. But that could soon change as legislation in California, Colorado, Nevada, and North Carolina, among other states, move closer to decriminalizing, and in some cases, legalizing psychedelic substances for mental health treatment.
Recent research found a growing number of Americans want to see more psychedelic treatment options for depression. High-profile politicians including New Jersey Senator Cory Booker (D) have supported the efforts to legalize psychedelics.
Related on Ethos:
